![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-real-world-parkinsons-disease-patient-characteristics-from-ongentys-opicapone-open-label-study-at-ana2022-301656404.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effect-on-comt-activity-at-the-2022-mds-international-congress-301624809.html
https://www.ema.europa.eu/en/documents/overview/ontilyv-epar-medicine-overview_en.pdf
https://www.pharmiweb.com/press-release/2021-09-14/new-study-designs-investigating-impact-of-ongentys-opicapone-on-non-motor-symptoms-presented-for-first-time-at-the-mds-virtual-congress-2021
https://www.recipharm.com/press/bial-and-recipharm-expand-long-term-supply-agreement-opicapone-api
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-once-daily-ongentys-opicapone-now-available-in-the-us-as-an-add-on-treatment-for-patients-with-parkinsons-disease-experiencing-off-episodes-301130083.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-data-analyses-demonstrating-efficacy-of-fda-approved-once-daily-ongentys-opicapone-in-patients-with-parkinsons-disease-at-the-mds-virtual-congress-2020-301128393.html